Australia markets open in 9 hours 45 minutes

Allakos Inc. (ALLK)

NasdaqGS - NasdaqGS Real-time price. Currency in USD
Add to watchlist
3.2750-0.1550 (-4.52%)
As of 10:14AM EDT. Market open.
Full screen
Trade prices are not sourced from all markets
Previous close3.4300
Open3.4400
Bid3.2200 x 900
Ask3.2300 x 2200
Day's range3.2250 - 3.4600
52-week range2.5400 - 112.8700
Volume221,369
Avg. volume1,013,056
Market cap180.685M
Beta (5Y monthly)0.96
PE ratio (TTM)N/A
EPS (TTM)N/A
Earnings dateN/A
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target estN/A
  • GlobeNewswire

    Allakos Provides Business Update and Reports First Quarter 2022 Financial Results

    REDWOOD CITY, Calif., May 06, 2022 (GLOBE NEWSWIRE) -- Allakos Inc. (the “Company”) (Nasdaq: ALLK), a biotechnology company developing lirentelimab (AK002) and AK006 for the treatment of allergic and inflammatory diseases, today provided a business update and reported financial results for the first quarter ended March 31, 2022. Recent Events Initiated a Phase 2 randomized, double-blind, placebo-controlled study of subcutaneous lirentelimab in patients with moderate-to-severe atopic dermatitis i

  • GlobeNewswire

    Allakos Provides Business Update and Reports Fourth Quarter and Full Year 2021 Financial Results

    REDWOOD CITY, Calif., March 01, 2022 (GLOBE NEWSWIRE) -- Allakos Inc. (the “Company”) (Nasdaq: ALLK), a biotechnology company developing lirentelimab (AK002) and AK006 for the treatment of allergic and inflammatory diseases, today provided a business update and reported financial results for the fourth quarter and full year ended December 31, 2021. Recent Events Initiated a Phase 2 randomized, double-blind, placebo-controlled study of subcutaneous lirentelimab in patients with moderate-to-severe

  • GlobeNewswire

    Allakos to Host Investor Day on February 15

    – Management will discuss lirentelimab development and Allakos pipeline – REDWOOD CITY, Calif., Feb. 01, 2022 (GLOBE NEWSWIRE) -- Allakos Inc. (the “Company” or “Allakos”) (Nasdaq: ALLK), a biotechnology company developing lirentelimab (AK002) for the treatment of eosinophil and mast cell-related diseases, today announced that it will host an Investor Day on February 15th starting at 8:00 am ET. Members of Allakos’ management team will be joined by prominent clinical leaders to discuss data from